中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
9期
1580-1582
,共3页
詹志学%林丽颖%刘薇薇%方云祥
詹誌學%林麗穎%劉薇薇%方雲祥
첨지학%림려영%류미미%방운상
神经生长因子%正己烷中毒%周围神经系统疾病%药物评价
神經生長因子%正己烷中毒%週圍神經繫統疾病%藥物評價
신경생장인자%정기완중독%주위신경계통질병%약물평개
Nerve growth factor%N-bexane intoxication%Peripheral nervous system agents%Drug evaluation
目的 评价注射用鼠神经生长因子(mNGF)治疗正己烷中毒性周围神经病的疗效和安全性.方法 54例正己烷中毒患者用mNGF治疗,肌内注射,18μg/次,1次/d,56 d 1个疗程,其中15例重度患者治疗2个疗程,治疗前和治疗后每14天检查症状、体征、日常生活能力,根据症状体征及日常生活能力增分情况评价疗效;治疗前和治疗后每28天进行实验室检查,每天记录不良事件,进行安全性评价.结果 症状体征以及日常生活能力于治疗后14 d开始增分,至治疗后的28~56 d与疗前比较,增分明显,差异有统计学意义(P<0.01).54例患者均未发生严重不良事件,实验室指标未发现明显异常.注射部位疼痛是主要的不良反应,发生率为68.5%(37/54).结论 mNGF治疗正己烷中毒性周围神经病疗效确定,安全性较好.
目的 評價註射用鼠神經生長因子(mNGF)治療正己烷中毒性週圍神經病的療效和安全性.方法 54例正己烷中毒患者用mNGF治療,肌內註射,18μg/次,1次/d,56 d 1箇療程,其中15例重度患者治療2箇療程,治療前和治療後每14天檢查癥狀、體徵、日常生活能力,根據癥狀體徵及日常生活能力增分情況評價療效;治療前和治療後每28天進行實驗室檢查,每天記錄不良事件,進行安全性評價.結果 癥狀體徵以及日常生活能力于治療後14 d開始增分,至治療後的28~56 d與療前比較,增分明顯,差異有統計學意義(P<0.01).54例患者均未髮生嚴重不良事件,實驗室指標未髮現明顯異常.註射部位疼痛是主要的不良反應,髮生率為68.5%(37/54).結論 mNGF治療正己烷中毒性週圍神經病療效確定,安全性較好.
목적 평개주사용서신경생장인자(mNGF)치료정기완중독성주위신경병적료효화안전성.방법 54례정기완중독환자용mNGF치료,기내주사,18μg/차,1차/d,56 d 1개료정,기중15례중도환자치료2개료정,치료전화치료후매14천검사증상、체정、일상생활능력,근거증상체정급일상생활능력증분정황평개료효;치료전화치료후매28천진행실험실검사,매천기록불량사건,진행안전성평개.결과 증상체정이급일상생활능력우치료후14 d개시증분,지치료후적28~56 d여료전비교,증분명현,차이유통계학의의(P<0.01).54례환자균미발생엄중불량사건,실험실지표미발현명현이상.주사부위동통시주요적불량반응,발생솔위68.5%(37/54).결론 mNGF치료정기완중독성주위신경병료효학정,안전성교호.
Objective To evaluate the efficacy and safety of mNGF to peripheral neuropathy induced by n-bexane. Methods 54 cases were treated with mNGF (18 μg i. m qd.) and the period of treatment is 56 days. 15 severe cases treated with two periods of treatment. Subjects received symptoms and signs of nerve system and activi-ties of daily living (ADL) scale were examined before and every 14 days after treated, The efficacy of mNGF was as-sessed by score increase of each index before and after treatment himself. To evaluate the safety, subjects received Is-boratory examinations before and every 28 days after treated, recorded adverse events everyday. Results During the trial, The indexes had improved remarkably in two weeks after the treatment , There were highly significant differ-ences in score increase after 4 ~ 8 weeks of treatment(P < 0. 01). It indicated that treatmented with mNGF was effec-tive. There were no severe adverse events (SAE) found among 54 trial subjects. There were no evident abnormalities in laboratory examinations before and after treatment. Pains of the injected sites are the main ADR, the incidence was 68.5% (37/54). Conclusion The results of the research indicated that mNGF clinical application could be consid-ered as safe and effective.